表紙
市場調査レポート

慢性腎臓病(CKD)に伴う高リン血症:パイプライン製品の分析

Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 224544
出版日 ページ情報 英文 73 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
慢性腎臓病(CKD)に伴う高リン血症:パイプライン製品の分析 Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2016
出版日: 2016年06月22日 ページ情報: 英文 73 Pages
概要

当レポートでは、慢性腎臓病に伴う高リン血症に対する治療薬の開発状況について調査しており、パイプライン製品の概要、治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

  • 調査範囲

慢性腎臓病に伴う高リン血症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

慢性腎臓病に伴う高リン血症:企業で開発中の治療薬

慢性腎臓病に伴う高リン血症:パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

慢性腎臓病に伴う高リン血症:企業で開発中の製品

慢性腎臓病に伴う高リン血症の治療薬開発に従事している企業

  • Amgen Inc.
  • Sanofi
  • OPKO Health, Inc.
  • Panion & Bf Biotech Inc.
  • Vifor Pharma AG

慢性腎臓病に伴う高リン血症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • ferric citrate
  • sucroferric oxyhydroxide
  • bixalomer
  • ferric citrate
  • fermagate
  • RDX-002
  • VS-501
  • VS-505
  • Fe-SAMMS

慢性腎臓病に伴う高リン血症:最近のパイプライン動向

慢性腎臓病に伴う高リン血症:休止中のプロジェクト

慢性腎臓病に伴う高リン血症:開発が中止された製品

慢性腎臓病に伴う高リン血症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8189IDB

Summary

Global Markets Direct's, 'Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2016', provides an overview of the Hyperphosphatemia In Chronic Kidney Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperphosphatemia In Chronic Kidney Disease and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hyperphosphatemia In Chronic Kidney Disease
  • The report reviews pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hyperphosphatemia In Chronic Kidney Disease therapeutics and enlists all their major and minor projects
  • The report assesses Hyperphosphatemia In Chronic Kidney Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hyperphosphatemia In Chronic Kidney Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hyperphosphatemia In Chronic Kidney Disease Overview
  • Therapeutics Development
    • Pipeline Products for Hyperphosphatemia In Chronic Kidney Disease - Overview
    • Pipeline Products for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis
  • Hyperphosphatemia In Chronic Kidney Disease - Therapeutics under Development by Companies
  • Hyperphosphatemia In Chronic Kidney Disease - Therapeutics under Investigation by Universities/Institutes
  • Hyperphosphatemia In Chronic Kidney Disease - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Hyperphosphatemia In Chronic Kidney Disease - Products under Development by Companies
  • Hyperphosphatemia In Chronic Kidney Disease - Products under Investigation by Universities/Institutes
  • Hyperphosphatemia In Chronic Kidney Disease - Companies Involved in Therapeutics Development
    • 3SBio Inc.
    • Ardelyx, Inc.
    • Daiichi Sankyo Company, Limited
    • Medice Arzneimittel Putter GmbH & Co. KG
    • OPKO Health, Inc.
    • Panion & Bf Biotech Inc
    • Shield Therapeutics Plc
    • Spectrum Pharmaceuticals, Inc.
    • Toray Industries, Inc.
  • Hyperphosphatemia In Chronic Kidney Disease - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • DS-2330 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fermagate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ferric citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JPH-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • niacinamide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PDX-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PT-20 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RDX-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sevelamer carbonate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target Phosphate for Hyperphosphatemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SPI-014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tenapanor hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRK-390 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VS-501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects
  • Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products
  • Hyperphosphatemia In Chronic Kidney Disease - Product Development Milestones
    • Featured News & Press Releases
      • Sep 24, 2015: Keryx Receives European Approval for Fexeric (ferric citrate coordination complex) for the Treatment of Hyperphosphatemia in Adults With Chronic Kidney Disease
      • May 07, 2015: Phosphate Therapeutics announces positive results in the PEACH pivotal study of its novel phosphate binder (PT20) for the treatment of hyperphosphataemia
      • Mar 04, 2015: Keryx Biopharmaceuticals Announces Publication of Auryxia (ferric citrate) Analysis in Journal of the American Society of Nephrology
      • Feb 02, 2015: Ardelyx Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor in Treating Hyperphosphatemia in Chronic Kidney Disease Patients on Hemodialysis
      • Jan 09, 2015: Keryx Biopharmaceuticals Turns to Veeva Commercial Cloud to Support First FDA-Approved Product Launch
      • Nov 17, 2014: Keryx Biopharmaceuticals Announces Trade Name Auryxia for Ferric Citrate
      • Nov 15, 2014: Keryx Biopharmaceuticals Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study
      • Oct 01, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Ferric Citrate Covering Orally Administrable Forms
      • Apr 09, 2014: Keryx Biopharmaceuticals Announces Zerenex Phase 2 Results in Non-Dialysis Dependent Chronic Kidney Disease Selected as a Late Breaking Oral Presentation at the Upcoming National Kidney Foundation 2014 Spring Clinical Meeting
      • Apr 02, 2014: Keryx Biopharmaceuticals Announces EMA Validation of Marketing Authorization Application for Zerenex
      • Mar 10, 2014: Keryx Biopharmaceuticals Announces Submission of a Marketing Authorization Application for Zerenex to the European Medicines Agency
      • Jan 17, 2014: Keryx Biopharmaceuticals Announces Marketing Approval of Ferric Citrate in Japan
      • Oct 21, 2013: Keryx Biopharmaceuticals Announces PDUFA Goal Date for Zerenex New Drug Application
      • Oct 17, 2013: Keryx Biopharmaceuticals' Zerenex (Ferric Citrate Coordination Complex) Data Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2013
      • Oct 08, 2013: Keryx Biopharmaceuticals Announces FDA Acceptance for Filing of Zerenex New Drug Application
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H1 2016
  • Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Hyperphosphatemia In Chronic Kidney Disease - Pipeline by 3SBio Inc., H1 2016
  • Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Ardelyx, Inc., H1 2016
  • Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Medice Arzneimittel Putter GmbH & Co. KG, H1 2016
  • Hyperphosphatemia In Chronic Kidney Disease - Pipeline by OPKO Health, Inc., H1 2016
  • Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Panion & Bf Biotech Inc, H1 2016
  • Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Shield Therapeutics Plc, H1 2016
  • Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016
  • Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Toray Industries, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects, H1 2016
  • Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H1 2016
  • Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top